Niklas Norén
Niklas Norén
Chief Science Officer, Uppsala Monitoring Centre, WHO Collaborating Centre for International Drug
Verified email at
Cited by
Cited by
Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers
G Hripcsak, JD Duke, NH Shah, CG Reich, V Huser, MJ Schuemie, ...
Studies in health technology and informatics 216, 574, 2015
Temporal pattern discovery in longitudinal electronic patient records
GN Norén, J Hopstadius, A Bate, K Star, IR Edwards
Data Mining and Knowledge Discovery 20 (3), 361-387, 2010
Extending the methods used to screen the WHO drug safety database towards analysis of complex associations and improved accuracy for rare events
GN Norén, A Bate, R Orre, IR Edwards
Statistics in medicine 25 (21), 3740-3757, 2006
Suspected adverse drug reactions reported for children worldwide
K Star, GN Norén, K Nordin, IR Edwards
Drug safety 34 (5), 415-428, 2011
A statistical methodology for drug–drug interaction surveillance
GN Norén, R Sundberg, A Bate, IR Edwards
Statistics in medicine 27 (16), 3057-3070, 2008
Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery
GN Norén, J Hopstadius, A Bate
Statistical methods in medical research 22 (1), 57-69, 2013
vigiGrade: a tool to identify well-documented individual case reports and highlight systematic data quality issues
T Bergvall, GN Norén, M Lindquist
Drug safety 37 (1), 65-77, 2014
Duplicate detection in adverse drug reaction surveillance
GN Norén, R Orre, A Bate, IR Edwards
Data Mining and Knowledge Discovery 14 (3), 305-328, 2007
Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®
RE Chandler, K Juhlin, J Fransson, O Caster, IR Edwards, GN Norén
Drug safety 40 (1), 81-90, 2017
Large‐scale regression‐based pattern discovery: the example of screening the WHO global drug safety database
O Caster, GN Norén, D Madigan, A Bate
Statistical Analysis and Data Mining: The ASA Data Science Journal 3 (4 …, 2010
Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank
O Caster, K Juhlin, S Watson, GN Norén
Drug safety 37 (8), 617-628, 2014
Good signal detection practices: evidence from IMI PROTECT
AFZ Wisniewski, A Bate, C Bousquet, A Brueckner, G Candore, K Juhlin, ...
Drug safety 39 (6), 469-490, 2016
Temporal pattern discovery for trends and transient effects: its application to patient records
GN Norén, A Bate, J Hopstadius, K Star, IR Edwards
Proceedings of the 14th ACM SIGKDD international conference on Knowledge …, 2008
Impact of stratification on adverse drug reaction surveillance
J Hopstadius, GN Norén, A Bate, IR Edwards
Drug safety 31 (11), 1035-1048, 2008
A hit-miss model for duplicate detection in the WHO drug safety database
GN Norén, R Orre, A Bate
Proceedings of the eleventh ACM SIGKDD international conference on Knowledge …, 2005
Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest
RD Boyce, PB Ryan, GN Norén, MJ Schuemie, C Reich, J Duke, ...
Drug safety 37 (8), 557-567, 2014
Earlier discovery of pregabalin’s dependence potential might have been possible
O Caster, IR Edwards, GN Norén, M Lindquist
European journal of clinical pharmacology 67 (3), 319-320, 2011
Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system
GN Norén, T Bergvall, PB Ryan, K Juhlin, MJ Schuemie, D Madigan
Drug safety 36 (1), 107-121, 2013
Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance
GN Norén, O Caster, K Juhlin, M Lindquist
Drug safety 37 (9), 655-659, 2014
Modern methods of pharmacovigilance: detecting adverse effects of drugs
GN Norén, IR Edwards
Clinical medicine 9 (5), 486, 2009
The system can't perform the operation now. Try again later.
Articles 1–20